S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024

OpGen (OPGN) Competitors

$0.62
+0.02 (+3.36%)
(As of 04/18/2024 ET)

OPGN vs. ACON, BGLC, PMD, CNTG, TTOO, DMTK, XGN, ADXS, HCTI, and HILS

Should you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Aclarion (ACON), BioNexus Gene Lab (BGLC), Psychemedics (PMD), Centogene (CNTG), T2 Biosystems (TTOO), DermTech (DMTK), Exagen (XGN), Ayala Pharmaceuticals (ADXS), Healthcare Triangle (HCTI), and Hillstream BioPharma (HILS). These companies are all part of the "medical" sector.

OpGen vs.

Aclarion (NASDAQ:ACON) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 2.7% of OpGen shares are owned by institutional investors. 22.3% of Aclarion shares are owned by company insiders. Comparatively, 1.3% of OpGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Aclarion and Aclarion both had 1 articles in the media. OpGen's average media sentiment score of 0.84 beat Aclarion's score of 0.00 indicating that Aclarion is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aclarion
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
OpGen
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclarion
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
OpGen
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

OpGen has a net margin of -852.18% compared to OpGen's net margin of -6,480.47%. Aclarion's return on equity of -316.30% beat OpGen's return on equity.

Company Net Margins Return on Equity Return on Assets
Aclarion-6,480.47% -724.93% -249.67%
OpGen -852.18%-316.30%-89.52%

Aclarion has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, OpGen has a beta of -0.71, suggesting that its share price is 171% less volatile than the S&P 500.

Aclarion has higher earnings, but lower revenue than OpGen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$75.40K28.17-$4.91MN/AN/A
OpGen$2.61M2.36-$37.28M-$6.51-0.09

OpGen received 300 more outperform votes than Aclarion when rated by MarketBeat users. However, 100.00% of users gave Aclarion an outperform vote while only 56.16% of users gave OpGen an outperform vote.

CompanyUnderperformOutperform
AclarionOutperform Votes
1
100.00%
Underperform Votes
No Votes
OpGenOutperform Votes
301
56.16%
Underperform Votes
235
43.84%

Summary

Aclarion beats OpGen on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPGN vs. The Competition

MetricOpGenMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$6.17M$2.03B$4.77B$7.44B
Dividend YieldN/A1.98%2.99%4.00%
P/E Ratio-0.097.96255.7719.15
Price / Sales2.36144.272,414.2285.81
Price / CashN/A447.1547.3635.12
Price / Book0.242.584.594.19
Net Income-$37.28M-$139.18M$104.50M$214.15M
7 Day Performance-13.24%-7.15%-5.35%-4.91%
1 Month Performance27.03%-6.96%-4.82%-3.49%
1 Year Performance-41.32%-17.22%8.53%3.83%

OpGen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACON
Aclarion
0 of 5 stars
$0.29
-6.5%
N/A-97.7%$2.07M$80,000.000.004
BGLC
BioNexus Gene Lab
0 of 5 stars
$0.63
+1.6%
N/AN/A$11.21M$10.93M-31.5027News Coverage
Gap Up
PMD
Psychemedics
0 of 5 stars
$2.54
-4.2%
N/A-52.1%$14.76M$22.10M-3.53133Gap Down
CNTG
Centogene
2.1214 of 5 stars
$0.48
-2.0%
$1.50
+212.4%
-33.2%$15.04M$50.03M0.00444Short Interest ↑
News Coverage
Gap Down
TTOO
T2 Biosystems
0 of 5 stars
$3.04
+2.4%
N/A-92.0%$16.75M$7.19M0.00158
DMTK
DermTech
0.75 of 5 stars
$0.61
-1.6%
$3.25
+429.1%
-87.1%$21.27M$15.30M-0.20206News Coverage
Gap Up
XGN
Exagen
4.3098 of 5 stars
$1.44
+0.7%
$6.00
+318.0%
-42.0%$24.75M$52.55M-1.07174
ADXS
Ayala Pharmaceuticals
0 of 5 stars
$0.60
-3.2%
N/A-54.0%$6.46M$3.24M0.00N/AAnalyst Report
Gap Up
HCTI
Healthcare Triangle
0 of 5 stars
$1.39
+2.2%
N/A-58.2%$6.46M$33.20M-0.4731News Coverage
Positive News
Gap Up
HILS
Hillstream BioPharma
0 of 5 stars
$0.37
+2.8%
N/A-59.5%$6.47MN/A-0.511

Related Companies and Tools

This page (NASDAQ:OPGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners